.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Rapid Readout: Clinical Updates in Multiple Sclerosis From CMSC 2020

EP. 1: The Multidisciplinary Theme of CMSC 2020

June 12th 2020

EP. 2: Progressive MS: The 2020 Whitaker Lecture

June 12th 2020

EP. 3: Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

June 12th 2020

EP. 4: Post Hoc Analysis: Phase 3 ASCLEPIOS I and II Trials in Relapsing MS

June 12th 2020

EP. 5: Primary Results From the ENSEMBLE PLUS Study

June 12th 2020

EP. 6: Post Hoc Analysis: Phase 3 EXPAND Trial in Secondary Progressive MS

June 12th 2020

EP. 7: Open-Label Extension: Phase 3 OPERA I and II Trials in Relapsing MS

June 12th 2020

EP. 8: CMSC Data Release: Abstract DXT58 and MS Risk Reduction

June 12th 2020

EP. 9: Open-Label Extension: BTKI in Relapsing MS Over 108 Weeks

June 12th 2020

Latest News

Crenezumab Does Not Reduce Clinical Decline in Adults With Early Alzheimer Disease

Advancing the Treatment Paradigm for Myasthenia Gravis and Looking Toward the Future

Institutional Perspectives in Neurology, Chaired by Riley Bove, MD

Majority of Canadian Physicians Treat Primary Headache Disorders With Nonsteroidal Anti-inflammatory Drugs, Dopamine Receptor Antagonists

View More News